Abbott designed the Volt PFA catheter for maneuverability, efficient ablation and thermal risk mitigation, said Dr.

Despite major product launches from diabetes rivals last year, Abbott’s diabetes unit brought in $1.8bn total Q1 sales to ...

Abbott Laboratories (NYSE:ABT) on Wednesday reported first-quarter sales of $10.36 billion, up 7.2% year over year, almost in ...

Abbott's diversified global supply chain and 25 new products in the pipeline position it well to navigate tariff impacts and ...

Abbott took "a deliberately very different development path ... for the waveform" behind its Volt PFA system, said Dr.

Abbott Laboratories ABT reported first-quarter 2025 adjusted earnings per share (EPS) of $1.09, which beat the Zacks ...

Abbott Labs recorded higher earnings and revenue in the first quarter as strong demand for its nutritional products and medical devices offset weakness in other segments. The healthcare products ...

Abbott Laboratories reported a strong start to 2025 with significant growth in sales and EPS, exceeding market expectations.

The Volt PFA System builds upon Abbott's leading electrophysiology (EP) portfolio by providing a single-catheter PFA approach, improving workflow by allowing for mapping, pacing, and ablating with ...

"The launch of Abbott's Volt PFA system marks a major milestone in the evolution of electrophysiology across Europe and signals we're moving beyond early therapy approaches to new systems that ...